News
* ONCOQUEST SIGNS A DEFINITIVE AGREEMENT TO SELL DRUG PORTFOLIO TO DUAL INDUSTRIAL FOR U.S. $300 MILLION AND COMMITMENT TO FUND THE OREGOVOMAB PHASE 3 CLINICAL TRIAL IN FRONTLINE OVARIAN CANCER ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback